Products
Efaprinermin Alfa Biosimilar Fusion Protein (GITR) for Research
Pre-Made Efaprinermin Alfa Biosimilar, Fusion Protein targeting TNFRSF18 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting AITR/CD357/ENERGEN/GITR/GITR-D is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Efaprinermin Alfa contains tumor necrosis factor superfamily protein TNFSF18 (human) trimer fusion protein with immunoglobulin g1 (human fc fragment). It is used for the high-value therapeutic targets for inflammatory or immune modulation in autoimmune diseases, transplant recipients, or cancers.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-810-1mg | 1mg | 3090 |
| GMP-Bios-INN-810-10mg | 10mg | |
| GMP-Bios-INN-810-100mg | 100mg | |
| GMP-Bios-INN-810-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Efaprinermin Alfa Biosimilar, Fusion Protein targeting TNFRSF18 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting AITR/CD357/ENERGEN/GITR/GITR-D |
| INN Name | Efaprinermin Alfa |
| Target | TNFRSF18 |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - [TNFSF18 (TNF superfamily member 18, AITRL, TL6, GITRL)]2 - IGHG1 Fc (Fragment constant) |
| VD LC | Fusion - [TNFSF18 (TNF superfamily member 18, AITRL, TL6, GITRL)]2 - IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | OncoMed Pharmaceuticals (Redwood City CA USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - TNFRSF18
1. Protein Fractalkine
2. Gene TNFRSF18
3. Organism Homo sapiens (Human)
Function
Chemokine that acts as a ligand for both CX3CR1 and integrins ITGAV:ITGB3 and ITGA4:ITGB1 (PubMed:9782118, PubMed:12055230, PubMed:23125415, PubMed:9931005, PubMed:21829356).
The CX3CR1-CX3CL1 signaling exerts distinct functions in different tissue compartments, such as immune response, inflammation, cell adhesion and chemotaxis (PubMed:9024663, PubMed:9177350, PubMed:9782118, PubMed:12055230).
Regulates leukocyte adhesion and migration processes at the endothelium (PubMed:9024663, PubMed:9177350).
Can activate integrins in both a CX3CR1-dependent and CX3CR1-independent manner (PubMed:23125415, PubMed:24789099).
In the presence of CX3CR1, activates integrins by binding to the classical ligand-binding site (site 1) in integrins (PubMed:23125415, PubMed:24789099).
In the absence of CX3CR1, binds to a second site (site 2) in integrins which is distinct from site 1 and enhances the binding of other integrin ligands to site 1 (PubMed:23125415, PubMed:24789099).
Processed fractalkine:
The soluble form is chemotactic for T-cells and monocytes, but not for neutrophils.
Fractalkine:
The membrane-bound form promotes adhesion of those leukocytes to endothelial cells.
